Karyopharm Therapeutics Inc   (KPTI)
Other Ticker:  
Price: $0.6758 $0.00 -0.471%
Day's High: $0.719 Week Perf: -4.9 %
Day's Low: $ 0.67 30 Day Perf: -17.59 %
Volume (M): 752 52 Wk High: $ 5.42
Volume (M$): $ 508 52 Wk Avg: $2.37
Open: $0.68 52 Wk Low: $0.67

 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 114
 Employees 315
 Revenues (TTM) (Millions $) 146
 Net Income (TTM) (Millions $) -140
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a biopharmaceutical company that is primarily focused on the development and commercialization of novel therapies for the treatment of cancer and other related diseases. The company's core technology platform is based on the identification and targeting of nuclear transport mechanisms, which are essential for the survival and growth of cancer cells.

The company was founded in 2008 and is headquartered in Newton, Massachusetts. It has operations in Europe and Asia, with strategic partners and collaborators spanning across North America, South America, Europe, Asia, and Africa.

Karyopharm's lead product candidate is XPOVIO (selinexor), which was approved by the US FDA in 2019 for the treatment of relapsed or refractory multiple myeloma. Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that targets the nuclear export protein XPO1 (exportin 1), causing a buildup of tumor suppressor proteins in the nucleus of cancer cells, leading to cell death.

Apart from XPOVIO, Karyopharm has a pipeline of drug candidates in various stages of development, targeting multiple cancer indications, including acute myeloid leukemia, liposarcoma, diffuse large B-cell lymphoma, and others. The company is also exploring the potential of its technology platform for the treatment of neurodegenerative diseases, inflammation, and viral infections.

Karyopharm has established collaborations with leading academic institutions, such as the National Cancer Institute, Dana-Farber Cancer Institute, and the Memorial Sloan Kettering Cancer Center, to support the preclinical and clinical development of its drug candidates. The company has also partnered with leading pharma companies, such as Biogen, Antengene, and Ono Pharmaceutical, to expand its market reach and accelerate the commercialization of its products.

In summary, Karyopharm Therapeutics Inc. is a biopharmaceutical company that is committed to developing and commercializing innovative therapies for cancer and other diseases, based on its nuclear transport technology platform. With a growing pipeline of drug candidates, a strong scientific and clinical team, and strategic collaborations with leading institutions and pharma companies, Karyopharm is well-positioned to realize its vision of transforming cancer care and improving patient outcomes.

   Company Address: 85 Wells Avenue, 2nd Floor Newton 2459 MA
   Company Phone Number: 658-0600   Stock Exchange / Ticker: NASDAQ KPTI
   KPTI is expected to report next financial results on February 16, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Announces Revenue of $0.016 Million, Paving the Way for an Investor Opportunity

Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc Faces Fiscal Disarray as Revenue Plummets

Financial News Report: Arrowhead Pharmaceuticals Inc Announces Q4 2023 Earnings
Arrowhead Pharmaceuticals Inc has reported its financial results for the fourth quarter of 2023 earnings season, revealing a significant increase in its loss per share. The company recorded a loss of $-1.02 per share, compared to $-0.81 per share in the same quarter the previous year, and a growth in loss from $-0.96 per share from the previous quarter.
Additionally, the company's revenue for the quarter declined by -49.02% to $16.10 million, down from $31.58 million in the same quarter a year before. However, sequentially, the revenue grew by 1.719% from $15.83 million.

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023

Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.

Earth Science Tech Inc

The company released Revenue of $1.92772 million, in the fiscal interval closing September 30 2023

Earth Science Tech Inc, a leading company in the science and wellness industry, has recently released its financial results for the fiscal interval closing September 30, 2023. The results indicate a significant improvement in revenue, earnings, and profit margins. Additionally, the company's stock performance has been impressive, reflecting strong investor confidence. This article will outline the key facts from the financial results and provide an overview of the context surrounding Earth Science Tech Inc's recent achievements.
Financial Results:
1. Revenue: Earth Science Tech Inc achieved revenue of $1.92772 million in the fiscal interval closing September 30, 2023. This represents a substantial increase compared to the same quarter the previous year.

Abeona Therapeutics Inc

The Major Pharmaceutical Preparations company has failed to turn into profitability in the wake of epic Surge in revenue in the fiscal interval closing September 30 2023

ABEO announced very robust Revenue elevation of 723.611 % year on year to $0.59 million in the fiscal three months closing Sep 30 2023, but lost money at $-0.48. ABEOs' results is for many as a surprise, while the Major Pharmaceutical Preparations company's displays revenue improvement while rest of Major Pharmaceutical Preparations sectors realizes -4.77% demise in business.


Karyopharm Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com